PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1397197
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1397197
Breast Lesion Localization Market Size and Share Report by Type, Usage (Breast Biopsy, Breast Conservation ), End User - Global Industry Demand Forecast to 2030
The breast lesion localization market was USD 410.4 million in 2023, which will reach USD 653.1 million by 2030, powering at a rate of 7% by the end of this decade.
This is because of the increasing breast cancer screening programs and better compensation conditions. Furthermore, breast cancer is the most prevalent disease in females and its incidence is increasing fast. For example, as per the data published by the IARC, breast cancer has now exceeded lung cancer as the most frequently diagnosed cancer all over the world.
The wire guided category led the industry, with a share of 40%, in 2023. This is because of its low cost, ease of usage, and the obtainability of numerous wire localization devices able to be connected to radiology imaging systems with the use of guided wire.
Also, it is expected that the benefits of the wire localization method, for example its affordability, precision, and efficiency, as opposed to other breast lesion localization procedures, will advance the method's acceptance.
Furthermore, the growing incidence of breast malignancy, the increasing count of breast operations, and the surging usage of the wire localization technique in diagnostic and therapeutic areas are powering the need for early detection and effective treatment, which will further drive the growth of the industry.
In 2023, the breast biopsy category had a larger market share, of 65%, and the requirement for breast biopsies will increase in the years to come. This is for the reason that the metrics are valued as per the volume of patients experiencing breast biopsies and the increasing consciousness of the benefits of a biopsy for early breast lesion diagnosis.
The lumpectomy category also has a considerable share in the industry. This has a lot to do with the benefits of lumpectomy, for example patients' breasts' appearance and sensation can be preserved and it has a minimally invasive nature and fast recovery. Thus, it is regularly preferred over other highly invasive procedures like mastectomy.
North America breast lesion localization market is the leader of the pack. This is because of the presence of an established healthcare system, the presence of notable manufacturers, increased consciousness of early discovery of breast cancer, simple FDA approval procedures, and high utilization of advanced devices in cancer treatment facilities, in the region. For example, MOLLI Surgical Inc. got the approval from the U.S. FDA in May 2021 for MOLLITM, a novel wire-free localization technique for breast cancer surgery.
It is due to the increasing occurrence of cancer all over the world, the demand for breast lesion localization is on the rise, and this trend will continue in the years to come as well.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by type
- 1.4.2. Market size breakdown, by usage
- 1.4.3. Market size breakdown, by end user
- 1.4.4. Market size breakdown, by region
- 1.4.5. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Type (2017-2030)
- 6.2.1. Radioisotope market revenue, by type (2017-2030)
- 6.3. Market Revenue, by Usage (2017-2030)
- 6.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 6.4. Market Revenue, by End User (2017-2030)
- 6.5. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Type (2017-2030)
- 7.2.1. Radioisotope market revenue, by type (2017-2030)
- 7.3. Market Revenue, by Usage (2017-2030)
- 7.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 7.4. Market Revenue, by End User (2017-2030)
- 7.5. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Type (2017-2030)
- 8.2.1. Radioisotope market revenue, by type (2017-2030)
- 8.3. Market Revenue, by Usage (2017-2030)
- 8.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 8.4. Market Revenue, by End User (2017-2030)
- 8.5. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Type (2017-2030)
- 9.2.1. Radioisotope market revenue, by type (2017-2030)
- 9.3. Market Revenue, by Usage (2017-2030)
- 9.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 9.4. Market Revenue, by End User (2017-2030)
- 9.5. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Type (2017-2030)
- 10.2.1. Radioisotope market revenue, by type (2017-2030)
- 10.3. Market Revenue, by Usage (2017-2030)
- 10.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 10.4. Market Revenue, by End User (2017-2030)
- 10.5. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Type (2017-2030)
- 11.2.1. Radioisotope market revenue, by type (2017-2030)
- 11.3. Market Revenue, by Usage (2017-2030)
- 11.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 11.4. Market Revenue, by End User (2017-2030)
- 11.5. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Type (2017-2030)
- 12.2.1. Radioisotope market revenue, by type (2017-2030)
- 12.3. Market Revenue, by Usage (2017-2030)
- 12.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 12.4. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Type (2017-2030)
- 13.2.1. Radioisotope market revenue, by type (2017-2030)
- 13.3. Market Revenue, by Usage (2017-2030)
- 13.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 13.4. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Type (2017-2030)
- 14.2.1. Radioisotope market revenue, by type (2017-2030)
- 14.3. Market Revenue, by Usage (2017-2030)
- 14.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 14.4. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Type (2017-2030)
- 15.2.1. Radioisotope market revenue, by type (2017-2030)
- 15.3. Market Revenue, by Usage (2017-2030)
- 15.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 15.4. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Type (2017-2030)
- 16.2.1. Radioisotope market revenue, by type (2017-2030)
- 16.3. Market Revenue, by Usage (2017-2030)
- 16.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 16.4. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Type (2017-2030)
- 17.2.1. Radioisotope market revenue, by type (2017-2030)
- 17.3. Market Revenue, by Usage (2017-2030)
- 17.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 17.4. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Type (2017-2030)
- 18.2.1. Radioisotope market revenue, by type (2017-2030)
- 18.3. Market Revenue, by Usage (2017-2030)
- 18.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 18.4. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Type (2017-2030)
- 19.2.1. Radioisotope market revenue, by type (2017-2030)
- 19.3. Market Revenue, by Usage (2017-2030)
- 19.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 19.4. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Type (2017-2030)
- 20.2.1. Radioisotope market revenue, by type (2017-2030)
- 20.3. Market Revenue, by Usage (2017-2030)
- 20.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 20.4. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Type (2017-2030)
- 21.2.1. Radioisotope market revenue, by type (2017-2030)
- 21.3. Market Revenue, by Usage (2017-2030)
- 21.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 21.4. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Type (2017-2030)
- 22.2.1. Radioisotope market revenue, by type (2017-2030)
- 22.3. Market Revenue, by Usage (2017-2030)
- 22.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 22.4. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Type (2017-2030)
- 23.2.1. Radioisotope market revenue, by type (2017-2030)
- 23.3. Market Revenue, by Usage (2017-2030)
- 23.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 23.4. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Type (2017-2030)
- 24.2.1. Radioisotope market revenue, by type (2017-2030)
- 24.3. Market Revenue, by Usage (2017-2030)
- 24.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 24.4. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Type (2017-2030)
- 25.2.1. Radioisotope market revenue, by type (2017-2030)
- 25.3. Market Revenue, by Usage (2017-2030)
- 25.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 25.4. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Type (2017-2030)
- 26.2.1. Radioisotope market revenue, by type (2017-2030)
- 26.3. Market Revenue, by Usage (2017-2030)
- 26.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 26.4. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Type (2017-2030)
- 27.2.1. Radioisotope market revenue, by type (2017-2030)
- 27.3. Market Revenue, by Usage (2017-2030)
- 27.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 27.4. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Type (2017-2030)
- 28.2.1. Radioisotope market revenue, by type (2017-2030)
- 28.3. Market Revenue, by Usage (2017-2030)
- 28.3.1. Breast biopsy market revenue, by usage (2017-2030)
- 28.4. Market Revenue, by End User (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Hologic Inc.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. Becton, Dickinson and Company
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Merit Medical Systems
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. Leica Biosystems Nussloch GmbH
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.5. Argon Medical Devices
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.6. Laurane Medical LLC
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.7. Endomagnetics Ltd.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.8. Intramedical Imaging, LLC
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.9. IsoAid
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.10. SurgicEye GmbH
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.11. MOLLI Surgical Inc.
- 30.11.1. Business overview
- 30.11.2. Product and service offerings
- 30.12. Vigeo S.r.l.
- 30.12.1. Business overview
- 30.12.2. Product and service offerings
- 30.13. BIOPSYBELL S.R.L
- 30.13.1. Business overview
- 30.13.2. Product and service offerings
- 30.14. STERYLAB S.r.l.
- 30.14.1. Business overview
- 30.14.2. Product and service offerings
- 30.15. Sirius Medical System B.V.
- 30.15.1. Business overview
- 30.15.2. Product and service offerings
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
